country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-143653

Copy Link Print Information

BCL6-IN-6

Kundenbewertung

Based on 1 Customer Validation

BCL6-IN-6 is a potent inhibitor of transcriptional repressor B-cell lymphoma 6 (BCL6). BCL6-IN-6 significantly blocks the interaction of BCL6 with its corepressors and reactivates BCL6 target genes in a dose-dependent manner. BCL6-IN-6 has the potential for the research of diffuse large B-cell lymphoma (DLBCL).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.10%
CAS. Nr.: 2408882-54-0
Formel: C₂₇H₃₁FN₆O₂S
Molecular Weight:522.64

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

BCL6-IN-6 Chemical Structure

CAS. Nr.: 2408882-54-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

BCL6^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
DOHH-2	IC₅₀	1 μM Compound: 28	Antiproliferative activity against BCL-6 dependent human DOHH-2 cells by CCK-8 assay Antiproliferative activity against BCL-6 dependent human DOHH-2 cells by CCK-8 assay	[PMID: 33844535]
DOHH-2	IC₅₀	1.21 μM Compound: 14j	Antiproliferative activity against human DOHH2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human DOHH2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31895575]
Farage	IC₅₀	1 μM Compound: 28	Antiproliferative activity against BCL-6 dependent human Farage cells by CCK-8 assay Antiproliferative activity against BCL-6 dependent human Farage cells by CCK-8 assay	[PMID: 33844535]
Farage	IC₅₀	1.26 μM Compound: 14j	Antiproliferative activity against human Farage cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human Farage cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31895575]
L02	IC₅₀	13.1 μM Compound: 14j	Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31895575]
NCM460	IC₅₀	32.4 μM Compound: 14j	Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human NCM460 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31895575]
OCI-Ly7	IC₅₀	1 μM Compound: 28	Antiproliferative activity against BCL-6 dependent human OCILY7 cells by CCK-8 assay Antiproliferative activity against BCL-6 dependent human OCILY7 cells by CCK-8 assay	[PMID: 33844535]
OCI-Ly7	IC₅₀	1.62 μM Compound: 14j	Antiproliferative activity against human OCI-LY7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human OCI-LY7 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31895575]
PNT1A	IC₅₀	8.13 μM Compound: 14j	Cytotoxicity against human PNT1A cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Cytotoxicity against human PNT1A cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31895575]
SUD4	IC₅₀	0.92 μM Compound: 14j	Antiproliferative activity against human SUDHL4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against human SUDHL4 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31895575]
SUD4	IC₅₀	1 μM Compound: 28	Antiproliferative activity against BCL-6 dependent human SU-DHL-4 cells by CCK-8 assay Antiproliferative activity against BCL-6 dependent human SU-DHL-4 cells by CCK-8 assay	[PMID: 33844535]
Toledo	IC₅₀	3.25 μM Compound: 14j	Antiproliferative activity against BCL6-negative human Toledo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay Antiproliferative activity against BCL6-negative human Toledo cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	[PMID: 31895575]
Toledo	IC₅₀	3.3 μM Compound: 28	Antiproliferative activity against BCL-6 independent human Toledo cells by CCK-8 assay Antiproliferative activity against BCL-6 independent human Toledo cells by CCK-8 assay	[PMID: 33844535]

Chemical Information

CAS. Nr. 2408882-54-0
Appearance Solid
Molecular Weight 522.64
Formel C₂₇H₃₁FN₆O₂S
Color Light yellow to yellow
SMILES

O=C(C1=CC=C(C2=CCCC2)S1)NC3=CC=C(NC4=NC(N5C[C@@H](C)N[C@@H](C)C5)=NC=C4F)C=C3OC
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 4 mg/mL (7.65 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9134 mL

9.5668 mL

19.1336 mL

5 mM

0.3827 mL

1.9134 mL

3.8267 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Guo W, et al. Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of N-Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth. J Med Chem. 2020;63(2):676-695. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9134 mL	9.5668 mL	19.1336 mL	47.8341 mL
DMSO	5 mM	0.3827 mL	1.9134 mL	3.8267 mL	9.5668 mL

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BCL6-IN-6

Anti-Blood Cancer Compound Library

Transcription Factor-Targeted Library

Heterocyclic Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BCL6-IN-6

Anti-Blood Cancer Compound Library

Transcription Factor-Targeted Library

Heterocyclic Compound Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

BCL6-IN-6 Related Classifications

HY-143653 Related Classifications